1. Generics Bulletin

Post-Brexit Divergence Would Harm UK Industry

BGMA Director General Warwick Smith Talks Brexit Implications

 
• By Dave Wallace

On the eve of the UK’s formal exit from the EU on 31 January, BGMA director general Warwick Smith has insisted that it is essential for the UK to stay as close as possible to the current European medicines framework following the conclusion of a transition period that is currently due to expire at the end of 2020.

Arrow_Flags_Pavement
Divergence from the European framework would harm industry and patients • Source: Shutterstock

Departing from the European regulatory framework for medicines following the UK’s exit from the EU would pose a significant risk for both the UK off-patent industry and for patient access to affordable medicines, according to Warwick Smith, director general of the British Generic Manufacturers Association and the British Biosimilars Association.

Speaking to Generics Bulletin just ahead of the UK’s formal departure from the EU, Smith noted that, for the moment, operations for generics and biosimilars players with UK interests would “carry on as normal” immediately after the formal exit date of 31 January

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation